Similar Items: Clinical Remission in Patients with Severe Eosinophilic Asthma – A Single-Arm Observational Study with Benralizumab
- Benralizumab Reduces Asthma Exacerbations and Costs Among Medicare Beneficiaries with Severe Asthma: The ZEPHYR-5 Study
- Feasibility of a 50% Dosing Interval Extension of Anti–IL-5 Biologics in Patients with Severe Asthma in Clinical Remission: A Real-World Validation Study
- A Case of Eosinophilic Granulomatosis with Polyangiitis Emerging During Benralizumab Therapy: Successful Management Through a Switch to Mepolizumab Therapy
- Differences in Type 2 Phenotype and Clinical Characteristics of Adult Asthma Patients with Different Severity, Across GINA Step 1 to 5 Asthma
- Clinical Remission in Severe T2‐High Asthma in Real Life After Anti‐IgE, Anti‐IL‐5 and Anti‐IL5R: A Potential Role for CRP as a Biomarker
- Assessment of Inhaled Corticosteroid Adherence in Adults with Severe Asthma Receiving Biologic Therapy: A Retrospective Observational Study